Volume 22, Issue S4 pp. 44-53
Article
Free to Read

Future directions in thrombolysis

James T. Willerson M.D.

Corresponding Author

James T. Willerson M.D.

Department of Medicine, University of Texas Medical School at Houston, and the Memorial-Hermann Hospital, and Texas Heart Institute in Houston, Texas, USA

Department of Medicine P.O. Box 20708 University of Texas Medical School at Houston Houston, TX 77225, USASearch for more papers by this author
Pierre Zoldhelyi M.D.

Pierre Zoldhelyi M.D.

Department of Medicine, University of Texas Medical School at Houston, and the Memorial-Hermann Hospital, and Texas Heart Institute in Houston, Texas, USA

Search for more papers by this author
First published: 03 February 2009
Citations: 7

Abstract

An extensive body of research conducted in the past 25 years has helped foster understanding of the mechanisms and pathogenesis of the acute coronary syndromes and occlusive disease. Thus, it is well established that thrombosis is caused by vascular injury and that immediate lysis of the arterial thrombus and subsequent prevention of thrombotic reocclusion are critical to the treatment of these disorders. Remarkable progress in the understanding of the biological and molecular mechanisms involved in vascular-wall-platelet interactions, platelet-platelet interactions, and coagulation has led to the identification of multiple targets for drug discovery and the development of numerous antithrombotic drugs. The purpose of this article is to review emerging antithrombotic therapies, introduce potential future molecular targets for drug discovery efforts, and discuss novel strategies for managing patients with coronary disease.

The full text of this article hosted at iucr.org is unavailable due to technical difficulties.